Omega Therapeutics looks to tap 'nature's operating system' to control gene expression

May 20, 2022 -- Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation, according to Thomas McCauley, PhD, chief scientific officer.

Omega's epigenomic programming platform is meant to direct the human genome to treat and cure disease by precisely controlling gene expression without altering native nucleic acid sequences, modulating insulated genomic domains to up- or downregulate single or multiple genes simultaneously.

"We believe this is applicable across the board really, certainly in monogenic diseases, but also importantly in complex multigenic diseases," McCauley told at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington.

The company's programmable mRNA therapeutics, which are called "epigenomic controllers" and are engineered to precisely tune genomic activity with high target specificity and durability, are composed of a DNA-binding domain and an epigenetic effector domain delivered as messenger RNA which modulates gene expression.

At ASGCT 2022, Omega unveiled preclinical data showing the potential of its epigenomic controllers to be developed as standalone therapy or in combination with standard of care therapies in non-small cell lung cancer.

Watch the video below to learn more.

Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...
Gene expression profile could enable rapid ID of antitumor immune cells
National Institutes of Health researchers, led by Dr. Steven Rosenberg, PhD, at the National Cancer Institute, have found unique expression profiles...
Scientists explain non-small cell lung cancer treatment resistance
A research group has shown why certain T cells do not respond to therapy in patients with non-small cell lung cancer who receive a therapy called immune...

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter